Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

European guidelines on managing adverse effects of medication for ADHD.

Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group..

Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. doi: 10.1007/s00787-010-0140-6.

2.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
3.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
4.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Review.

PMID:
16735655
5.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Review.

PMID:
24982313
6.
7.

Close up on atomoxetine: a nonstimulant choice for treating ADHD.

Allen C, Pitcock J.

Adv Nurse Pract. 2006 Mar;14(3):39-40, 42-3, 78. Review. No abstract available.

PMID:
16548127
8.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
9.
10.

Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J; European ADHD Guidelines Group..

J Child Psychol Psychiatry. 2013 Mar;54(3):227-46. doi: 10.1111/jcpp.12036. Review.

PMID:
23294014
11.

[My child is so restless].

Schlamp D.

MMW Fortschr Med. 2007 Mar 8;149(10):39-40. Review. German.

PMID:
17408047
12.

[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E.

Z Kinder Jugendpsychiatr Psychother. 2008 Mar;36(2):97-106; quiz 106-7. doi: 10.1024/1422-4917.36.2.97. Review. German.

PMID:
18622939
13.

ADHD treatments, sleep, and sleep problems: complex associations.

Stein MA, Weiss M, Hlavaty L.

Neurotherapeutics. 2012 Jul;9(3):509-17. doi: 10.1007/s13311-012-0130-0. Review.

14.

Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder.

Vaughan B, Kratochvil CJ.

Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55. doi: 10.1016/j.chc.2012.07.005. Review.

PMID:
23040908
15.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.

Awudu GA, Besag FM.

Drug Saf. 2014 Sep;37(9):661-76. doi: 10.1007/s40264-014-0201-8. Review.

PMID:
25124483
16.

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E.

Eur Child Adolesc Psychiatry. 2006 Dec;15(8):476-95. Review.

PMID:
16680409
17.

Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.

Hammerness PG, Surman CB, Chilton A.

Curr Psychiatry Rep. 2011 Oct;13(5):357-63. doi: 10.1007/s11920-011-0213-3. Review.

PMID:
21698412
18.

Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.

Fredriksen M, Peleikis DE.

Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):23-31. doi: 10.1111/bcpt.12477. Review.

19.

[Cardiovascular risk assessment for the use of ADHD drugs in children].

Berg A, Bråtane E, Odland HH, Brudvik C, Rosland B, Hirth A.

Tidsskr Nor Laegeforen. 2014 Apr 8;134(7):710-4. doi: 10.4045/tidsskr.13.0565. Review. Norwegian.

20.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Stiefel G, Besag FM.

Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000. Review.

PMID:
20812768
Items per page

Supplemental Content

Support Center